Javelin Pharmaceuticals, Inc

(AMEX:JAV)
  Sep 30, 2008 Jun 30, 2008 Mar 31, 2008 Dec 31, 2007
Operating revenue
Total Revenue 366 180 66 —
Operating Revenue 366 180 66 —
Adjustments To Revenue — — — —
Cost Of Sales 210 73 0 -4
Cost Of Sales With Depreciation 272 129 50 —
Gross Operating Profit 156 106 66 4
Operating Expenses
Research And Development Expenses 6,888 4,490 5,665 5,665
Selling General And Administrative Expenses 4,164 4,760 4,476 4,527
Advertising Expenses — — — —
Operating Income Before Depreciation -10,896 -9,144 -10,076 -10,187
Operating Income -11,044 -9,280 -10,167 -10,220
Depreciation 148 136 91 33
Depreciation Unreconciled 86 80 41 29
Amortization — — — —
Amortization Of Intangibles — — — —
Operating Income After Depreciation -11,044 -9,280 -10,167 -10,220
Non Operating Expenses
Interest Expense — — — —
Pre Tax Income -10,847 -9,060 -9,773 -9,674
Income Taxes 23 — — —
Minority Interest — — — —
Income Before Income Taxes -10,847 — — —
Net Income From Continuing Operations -10,871 -9,060 -9,773 -9,674
Net Income From Discontinued Operations — — — —
Net Income From Total Operations -10,871 -9,060 -9,773 -9,674
Non Recurring Events
Extraordinary Income Losses — — — —
Income From Cummulated Effect Of Accounting Changes — — — —
Income From Tax Loss Carryforward — — — —
Other Gains And Losses — — — —
Total Net Income -10,871 -9,060 -9,773 -9,674
Normalized Income -10,871 -9,060 -9,773 -9,674
NetIncome Available For Common -10,871 -9,060 -9,773 -9,674
Preferred Dividends — — — —
Excise Taxes — — — —